The transaction information is sourced from an SEC filing published on the SEC EDGAR platform on August 13, 2026. While the specific form type is not identified in the available materials, the filing represents the primary disclosure document for this matter. The deal's current status is pending regulatory approval or clearance.
Sangamo Therapeutics has retained a comprehensive advisory team across financial and legal disciplines. On the financial side, the company engaged MERU, LLC to serve as its financial advisor, and Raymond James to serve as its restructuring banker. These advisors are working in tandem to manage the financial and restructuring aspects of the asset sale process. The company's legal counsel consists of two firms: Cooley LLP and Richards, Layton & Finger, PA, both of which are representing Sangamo in the transaction.
No additional information regarding specific deal terms, consideration structure, or the identity of the acquiring party or parties has been disclosed in the available materials. The transaction timeline, including any expected closing date, has not been specified. Similarly, no details regarding the composition of the assets being sold, any earn-out provisions, assumed liabilities, or other material transaction structure elements have been made public. The 263.55 million USD valuation represents the sole quantitative metric disclosed for this restructuring transaction.